Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360665 | 0.90 | USP2 (0.61) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL3962083 | 0.88 | USP2 (0.59) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL10532497 | 0.88 | USP2 (0.59) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL23710762 | 0.82 | USP2 (0.68) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| Ether SCHEMBL6808285 | 0.79 | USP2 (0.64) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL15463130 | 0.79 | USP2 (0.48) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL2755517 | 0.79 | USP2 (0.52) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL25862696 | 0.79 | USP2 (0.52) | USP2ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL12533623 | 0.79 | — | — | |
| SCHEMBL33689 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170231896-A1 | SILICONE ELASTOMER IN OILY PHASE | L'OREAL (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20120301417-A1 | COMPOSITION FOR MAKING UP THE EYELASHES OR EYEBROWS, COMBINATION AND METHODS | L'OREAL (FR) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231896-A1 | SILICONE ELASTOMER IN OILY PHASE | LIPA, DAGLB, MGLL | USP2 1983/4885ALDH1A1 3450/4885HSD17B10 159/4885 |
| US-20120301417-A1 | COMPOSITION FOR MAKING UP THE EYELASHES OR EYEBROWS, COMBINATION AND METHODS | KRT18, SMCHD1, MDC1 | USP2 1205/4885ALDH1A1 4463/4885HSD17B10 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.